CAST · Active Monitoring of Cancer As An Alternative To Surgery
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2019-11-01 → 2024-10-31
- Финансиране от ЕС
- 4 057 659 €
- Участници
- 14
- Схема
- MSCA-ITN
Линиите свързват координатора с партньорите.
Накратко на български
Нови технологии за мониторинг, като течни биопсии и камери, се тестват, за да се определи дали операцията при рак е необходима. Това помага за по-добър подбор на пациентите и подобрява качеството им на живот чрез персонализирано лечение.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Active Monitoring of Cancer As An Alternative To Surgery
What is the problem/issue being addressed: CAST is to implement a paradigm change for a novel approach in deciding if cancer surgery is needed. Therefore, our aim will be to clinically translate innovative new monitoring technologies from the industry. This will provide better patient selection and increase the surveillance window to allow for better treatment options over time and avoid surgery. This will involve developing new ‘watch and wait’ strategies to study the behaviour of the cancer so that any risks can be minimized. This would lead to a better clinical outcome and quality of life (QOL) for the patient and maximize the benefits of an active monitoring policy for both the patient and the healthcare system. Why is it important for society: i) Better understand the importance of watch and wait and to estimate the risks to either perform or not to perform cancer surgery; ii) Address how the implementation of a more patient-tailored approach in cancer treatment may be utilised; iii) Address how the implementation of novel monitoring technologies for the surgeon may be utilised to open-up a risk-free window of opportunity for active surveillance; and iv) Even if surgery is determined to be needed, what are the alternative interventions to preserve the quality of life in patients. What are the overall objectives: i) A consensus for full implementation of watch and wait for different cancers involving shared databases, training facilities and determined best practice for patient management; ii) Beyond state of art technologies, including camera systems, hardware and liquid biopsies, that will allow better prognosis and management of patients; and iii) Improved methods for the localised delivery of immunotherapy or radiotherapy.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
When a patient is discovered to have cancer, one of the primary goals is to have the tumour removed by surgery. Althoughthis provides excellent oncological control, it is associated with morbidity and functional problems in cancer survivors. Recentstudies have shown that the immediacy to perform a resection does not always lead to improved clinical outcome.Furthermore, cancer surgery can often lead to complications where the quality of life for the patient is compromised by toxicside effects and /or damage to nerves, organs or healthy tissues. A number of recent clinical trials in the field of cancersurgery have advocated the concept of watch and wait, watchful waiting, active monitoring or surveillance, which are termsused to describe a monitoring strategy for cancer. The concept may be antithetical but the functional advantage of thesealternatives is clear even though there is some concern about the risk. Though the evidence is still weak, current studiessuggest that with adequate selection and follow-up, this oncological risk is small. A major consideration for clinicians is nowto maintain quality of life for all patients. Our objective in this proposal is to implement novel approaches so that cancersurgery can be avoided, where we aim to (a) develop new monitoring technologies from industry so that the surveillancewindow can be increased to allow for better treatment options over time and to avoid surgery, (b) develop new ‘watch andwait’ strategies in order to study the behaviour of the cancer so that any risks to the patient can be minimised leading to abetter clinical outcome and (c) train a new generation of preclinical and clinical scientists to be able to implement this newconcept as standard of care and to maximise the benefits of an active monitoring policy.
Оригинален текст от CORDIS (на английски).
Участници
- STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS · AmsterdamКоординаторНидерландия
- ACADEMISCH ZIEKENHUIS LEIDEN · LeidenНидерландия
- EDINBURGH MOLECULAR IMAGING LIMITED · EdinburghОбединеното кралство
- FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · LISBOAПортугалия
- KAROLINSKA INSTITUTET · STOCKHOLMШвеция
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENГермания
- PERCUROS BV · 's-Gravenhage (Den Haag)Нидерландия
- SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENTWICKLUNG GMBH · BAYREUTHГермания
- SURGIMAB SAS · MontpellierФранция
- THE UNIVERSITY OF LIVERPOOL · LIVERPOOLОбединеното кралство
- THE UNIVERSITY OF MANCHESTER · ManchesterОбединеното кралство
- UNIVERSITA DEGLI STUDI DI CAMERINO · CamerinoИталия
- UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS · GoettingenГермания
- UNIVERSITE DE STRASBOURG · StrasbourgФранция
Връзки
- Виж в CORDIS
- DOI: 10.3030/857894
- https://cast-cancer.eu
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5ca76bd3f&appId=PPGMS
Данни: CORDIS, © Европейски съюз
